Nanomedicine based on nucleic acids: Pharmacokinetic and pharmacodynamic perspectives

Current Pharmaceutical Biotechnology

Volumn 15, Issue 9, 2015, Pages 829-838

  Zhou, Chenguang ^a,d   Yang, Zhaogang ^a,b   Teng, Lesheng ^a,c  

^a OHIO STATE UNIVERSITY   (United States)

^b Ohio State University   (United States)

^c JILIN UNIVERSITY   (China)

^d GENENTECH INC   (United States)

Author keywords

Antisense oligonucleotide; Gene therapy; Intracellular trafficking; MicroRNA; Nanomedicine; Pharmacodynamic; Pharmacokinetic; Plasmid DNA; Small interfering RNA

Indexed keywords

ALN PCS02; ALN TTR01; ALN TTR02; ALN VSP02; ATU 027; CALAA 01; DCR MYC; LOW DENSITY LIPOPROTEIN; NANOROD; ND L02S0201; NUCLEIC ACID; PRO 040201; SIG 12DLODER; SIRNA EPHA2 DOPC; TKM 080301; TKM 100201; UNCLASSIFIED DRUG; NANOPARTICLE;

ADVANCED CANCER; AMYLOIDOSIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOAVAILABILITY; CELL MIGRATION; CELLULAR DISTRIBUTION; COMPARATIVE STUDY; DNA DEGRADATION; DRUG EXPOSURE; DRUG STABILITY; EBOLA HEMORRHAGIC FEVER; ENDOCYTOSIS; ENZYMATIC DEGRADATION; GENE EXPRESSION; GENE TRANSFER; HALF LIFE TIME; HUMAN; HYPERCHOLESTEROLEMIA; LIVER CANCER; LIVER CIRRHOSIS; LUMINESCENCE; MATHEMATICAL ANALYSIS; MULTIPLE MYELOMA; NANOMEDICINE; PANCREAS CANCER; PANCREAS CARCINOMA; PHAGOCYTOSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PINOCYTOSIS; REGULATORY MECHANISM; RENAL CLEARANCE; RETICULOENDOTHELIAL SYSTEM; SIGNAL TRANSDUCTION; SOLID TUMOR; TREATMENT OUTCOME; ANIMAL; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; HUMANS; NANOMEDICINE; NANOPARTICLES; NUCLEIC ACIDS;

EID: 84935870981     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/1389201015666141020155620     Document Type: Article

References (106)

1. Zhou, C. Nanocarriers for therapeutic nucleic acid delivery. Doctoral dissertation 2012.
2. Elsabahy, M.; Nazarali, A.; Foldvari, M. Non-viral nucleic acid delivery: Key challenges and future directions. Curr. Drug Deliv., 2011, 8(3), 235-44.
3. Zhou, C.; Yu, B.; Yang, X.; Huo, T.; Lee, L.J.; Barth, R.F.; Lee, R.J. Lipid-coated nano-calcium-phosphate (LNCP) for gene delivery. Int. J. Pharm., 2010, 392(1-2), 201-208.
4. Zhou, C.; Zhang, Y.; Lee, L.J.; Lee, R.J. Novel lipoidal aminebased nanocarrier formulations for siRNA delivery. Therapeut. Deliv., 2012, 3(6), 715-723.
5. Zhou, C.; Mao, Y.; Sugimoto, Y.; Zhang, Y.; Kanthamneni, N.; Yu, B.; Brueggemeier, R.W.; Lee, L.J.; Lee, R.J. SPANosomes as delivery vehicles for small interfering RNA (siRNA). Mol. Pharm., 2012, 9(2), 201-210.
6. Ogris, M.; Wagner, E. To be targeted: Is the magic bullet concept a viable option for synthetic nucleic acid therapeutics? Hum. Gene Ther., 2011, 22(7), 799-807.
7. Bumcrot, D.; Manoharan, M.; Koteliansky, V.; Sah, D.W. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat. Chem. Biol., 2006, 2(12), 711-719.
8. Dykxhoorn, D. M.; Palliser, D.; Lieberman, J. The silent treatment: siRNAs as small molecule drugs. Gene Ther., 2006, 13(6), 541-552.
9. Kota, J.; Chivukula, R.R.; O'Donnell, K.A.; Wentzel, E.A.; Montgomery, C.L.; Hwang, H.W.; Chang, T.C.; Vivekanandan, P.; Torbenson, M.; Clark, K.R.; Mendell, J.R.; Mendell, J.T. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell, 2009, 137(6), 1005-1017.
10. Wang, B.; Majumder, S.; Nuovo, G.; Kutay, H.; Volinia, S.; Patel, T.; Schmittgen, T. D.; Croce, C.; Ghoshal, K.; Jacob, S.T. Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice. Hepatology, 2009, 50(4), 1152-1161.
11. Esau, C.; Davis, S.; Murray, S.F.; Yu, X.X.; Pandey, S.K.; Pear, M.; Watts, L.; Booten, S.L.; Graham, M.; McKay, R.; Subramaniam, A.; Propp, S.; Lollo, B.A.; Freier, S.; Bennett, C.F.; Bhanot, S.; Monia, B.P. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab., 2006, 3(2), 87-98.
12. Lanford, R.E.; Hildebrandt-Eriksen, E.S.; Petri, A.; Persson, R.; Lindow, M.; Munk, M.E.; Kauppinen, S.; Orum, H. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science, 2010, 327(5962), 198-201.
13. Zhou, C.; Yu, B.; Zhang, Y.; Lee, L.J.; Lee, R.J. Design, synthesis of new lipid-like molecules for efficient small interfering RNA (siRNA) delivery and study of their cellular entry pathways. AAPS J., 2011, 13(S2), Abstract W4385.
14. Morille, M.; Passirani, C.; Vonarbourg, A.; Clavreul, A.; Benoit, J.P. Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials, 2008, 29(24-25), 3477- 3496.
15. Huang, X.; Schwind, S.; Yu, B.; Santhanam, R.; Wang, H.; Hoellerbauer, P.; Mims, A.; Klisovic, R.; Walker, A.R.; Chan, K.K.; Blum, W.; Perrotti, D.; Byrd, J.C.; Bloomfield, C.D.; Caligiuri, M.A.; Lee, R.J.; Garzon, R.; Muthusamy, N.; Lee, L.J.; Marcucci, G. Targeted delivery of microRNA-29b by transferrinconjugated anionic lipopolyplex nanoparticles: A novel therapeutic strategy in acute myeloid leukemia. Clin. Cancer Res., 2013, 19(9), 2355-2367.
16. Zhang, S.; Zhao, B.; Jiang, H.; Wang, B.; Ma, B.3, Cationic lipids and polymers mediated vectors for delivery of siRNA. J. Control Release, 2007, 123(1), 1-10.
17. Akhtar, S.; Benter, I.F. Nonviral delivery of synthetic siRNAs in vivo. J. Clin. Invest., 2007, 117(12), 3623-3632.
18. Weinstein, S.; Peer, D. RNAi nanomedicines: challenges and opportunities within the immune system. Nanotechnology, 2010, 21(23), 232001.
19. Ozpolat, B.; Sood, A.K.; Lopez-Berestein, G. Nanomedicine based approaches for the delivery of siRNA in cancer. J. Intern. Med., 2010, 267(1), 44-53.
20. Ocana, A.; Pandiella, A.; Siu, L.L.; Tannock, I.F. Preclinical development of molecular-targeted agents for cancer. Nat. Rev. Clin. Oncol., 2010, 8(4), 200-209.
21. Peer, D.; Karp, J.M.; Hong, S.; Farokhzad, O.C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol., 2007, 2(12), 751-760.
22. Yim, K.L.; Cunningham, D. Targeted drug therapies and cancer. Recent Results Cancer Res., 2011, 185, 159-171.
23. Farrell, D.; Alper, J.; Ptak, K.; Panaro, N. J.; Grodzinski, P.; Barker, A. D. Recent advances from the National Cancer Institute Alliance for Nanotechnology in Cancer. ACS Nano, 2010, 4(2), 589-594.
24. Akinc, A.; Goldberg, M.; Qin, J.; Dorkin, J.R.; Gamba-Vitalo, C.; Maier, M.; Jayaprakash, K.N.; Jayaraman, M.; Rajeev, K.G.; Manoharan, M.; Koteliansky, V.; Rohl, I.; Leshchiner, E.S.; Langer, R.; Anderson, D.G. Development of lipidoid-siRNA formulations for systemic delivery to the liver. Mol. Ther., 2009, 17(5), 872-879.
25. Zhou, X.; Zhang, M.; Yung, B.; Li, H.; Zhou, C.; Lee, L.J.; Lee, R.J. Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma. Int. J. Nanomedicine, 2012, 7, 5465- 5474.
26. Dohmen, C.; Frohlich, T.; Lachelt, U.; Rohl, I.; Vornlocher, H.P.; Hadwiger, P.; Wagner, E. Defined folate-PEG-siRNA conjugates for receptor-specific gene silencing. Mol. Ther. Nucleic Acids, 2012, 1, e7.
27. Ferrari, M. Cancer nanotechnology: Opportunities and challenges. Nat. Rev. Cancer, 2005, 5(3), 161-171.
28. Zhou, C.; Zhang, Y.; Yu, B.; Phelps, M.A.; Lee, L.J.; Lee, R.J. Comparative cellular pharmacokinetics and pharmacodynamics of siRNA delivery by SPANosomes and by cationic liposomes. Nanomedicine, 2013, 9(4), 504-513.
29. Paecharoenchai, O.; Teng, L.; Yung, B.C.; Teng, L.; Opanasopit, P.; Lee, R. J., Nonionic surfactant vesicles for delivery of RNAi therapeutics. Nanomedicine, (Lond) 2013, 8(11), 1865-1873.
30. Banks, G.A.; Roselli, R.J.; Chen, R.; Giorgio, T.D. A model for the analysis of nonviral gene therapy. Gene Ther., 2003, 10(20), 1766- 1775.
31. Whitehead, K.A.; Langer, R.; Anderson, D.G. Knocking down barriers: Advances in siRNA delivery. Nat. Rev. Drug Discov., 2009, 8(2), 129-138.
32. Juliano, R.; Alam, M.R.; Dixit, V.; Kang, H. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res., 2008, 36(12), 4158-4171.
33. Rippe, B.; Rosengren, B. I.; Carlsson, O.; Venturoli, D. Transendothelial transport: The vesicle controversy. J. Vasc. Res., 2002, 39(5), 375-390.
34. Zamecnik, J.; Vargova, L.; Homola, A.; Kodet, R.; Sykova, E. Extracellular matrix glycoproteins and diffusion barriers in human astrocytic tumours. Neuropathol Appl. Neurobiol., 2004, 30(4), 338-350.
35. Oliveira, S.; van Rooy, I.; Kranenburg, O.; Storm, G.; Schiffelers, R.M. Fusogenic peptides enhance endosomal escape improving siRNA-induced silencing of oncogenes. Int. J. Pharm., 2007, 331(2), 211-214.
36. Medina-Kauwe, L.K.; Xie, J.; Hamm-Alvarez, S. Intracellular trafficking of nonviral vectors. Gene Ther., 2005, 12(24), 1734- 1751.
37. Di Guglielmo, G.M.; Le Roy, C.; Goodfellow, A.F.; Wrana, J.L. Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover. Nat. Cell Biol., 2003, 5(5), 410-421.
38. Khalil, I.A.; Kogure, K.; Akita, H.; Harashima, H. Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery. Pharmacol. Rev., 2006, 58(1), 32-45.
39. Kim, S.S.; Garg, H.; Joshi, A.; Manjunath, N. Strategies for targeted nonviral delivery of siRNAs in vivo. Trends Mol. Med., 2009, 15(11), 491-500.
40. Aboul-Fadl, T. Antisense oligonucleotides: the state of the art. Curr. Med. Chem., 2005, 12(19), 2193-2214.
41. Tarahovsky, Y.S. Cell transfection by DNA-lipid complexes - lipoplexes. Biochemistry (Mosc) 2009, 74(12), 1293-1304.
42. Escriou, V.; Carriere, M.; Bussone, F.; Wils, P.; Scherman, D. Critical assessment of the nuclear import of plasmid during cationic lipid-mediated gene transfer. J. Gene Med., 2001, 3(2), 179-187.
43. Li, S.D.; Huang, L. Pharmacokinetics and biodistribution of nanoparticles. Mol. Pharm., 2008, 5(4), 496-504.
44. Heidel, J.D.; Davis, M.E. Clinical developments in nanotechnology for cancer therapy. Pharm. Res., 2011, 28(2), 187-199.
45. Choi, C.H.; Alabi, C.A.; Webster, P.; Davis, M.E. Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc. Natl. Acad. Sci. USA, 2010, 107(3), 1235- 1240.
46. Mamot, C.; Drummond, D.C.; Noble, C.O.; Kallab, V.; Guo, Z.; Hong, K.; Kirpotin, D.B.; Park, J.W. Epidermal growth factor receptor- targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res., 2005, 65(24), 11631-11638.
47. Bartlett, D.W.; Su, H.; Hildebrandt, I.J.; Weber, W.A.; Davis, M.E. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc. Natl. Acad. Sci. USA 2007, 104(39), 15549-11554.
48. Laginha, K.M.; Verwoert, S.; Charrois, G.J.; Allen, T.M. Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clin. Cancer Res., 2005, 11(19 Pt 1), 6944-6949.
49. Semple, S.C.; Akinc, A.; Chen, J.; Sandhu, A.P.; Mui, B.L.; Cho, C.K.; Sah, D.W.; Stebbing, D.; Crosley, E.J.; Yaworski, E.; Hafez, I.M.; Dorkin, J.R.; Qin, J.; Lam, K.; Rajeev, K.G.; Wong, K.F.; Jeffs, L.B.; Nechev, L.; Eisenhardt, M.L.; Jayaraman, M.; Kazem, M.; Maier, M.A.; Srinivasulu, M.; Weinstein, M.J.; Chen, Q.; Alvarez, R.; Barros, S.A.; De, S.; Klimuk, S.K.; Borland, T.; Kosovrasti, V.; Cantley, W.L.; Tam, Y.K.; Manoharan, M.; Ciufolini, M.A.; Tracy, M.A.; de Fougerolles, A.; MacLachlan, I.; Cullis, P.R.; Madden, T.D.; Hope, M.J. Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol., 2010, 28(2), 172-176.
50. Zhou, C.; Lee, L.J.; Lee, R.J. Cellular pharmacokinetics (PK) and target gene knockdown of surfactant- and lipid-based nanocarriers (NCs) of siRNA. AAPS J., 2011, 13(S1), Abstract W3028.
51. Parra-Guillen, Z.P.; Gonzalez-Aseguinolaza, G.; Berraondo, P.; Troconiz, I.F., Gene therapy: A pharmacokinetic/pharmacodynamic modelling overview. Pharm. Res., 2010, 27(8), 1487-1497.
52. Bertrand, N.; Wu, J.; Xu, X.; Kamaly, N.; Farokhzad, O.C. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv. Drug Deliv. Rev., 2014, 66, 2-25.
53. Biswas, S.; Torchilin, V.P. Nanopreparations for organelle-specific delivery in cancer. Adv. Drug Deliv. Rev., 2014, 66, 26-41.
54. Fattal, E.; Barratt, G. Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA. Br. J. Pharmacol., 2009, 157(2), 179-194.
55. Fang, C.; Shi, B.; Pei, Y.Y.; Hong, M.H.; Wu, J.; Chen, H.Z. In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size. Eur. J. Pharm. Sci., 2006, 27(1), 27-36.
56. Levchenko, T.S.; Rammohan, R.; Lukyanov, A.N.; Whiteman, K.R.; Torchilin, V.P. Liposome clearance in mice: The effect of a separate and combined presence of surface charge and polymer coating. Int. J. Pharm., 2002, 240(1-2), 95-102.
57. Sadzuka, Y.; Hirotsu, S.; Hirota, S. Effect of liposomalization on the antitumor activity, side-effects and tissue distribution of CPT- 11. Cancer Lett., 1998, 127(1-2), 99-106.
58. Shukla, S.; Ablack, A.L.; Wen, A.M.; Lee, K.L.; Lewis, J.D.; Steinmetz, N.F. Increased tumor homing and tissue penetration of the filamentous plant viral nanoparticle Potato virus X. Mol. Pharm., 2013, 10(1), 33-42.
59. Zhang, H.; Mao, Y.; Zhang, F.; Ye, C.; Tong, H.; Su, Y.; Zhu, J. The inhibitory effect of a new scFv/tP protein as siRNA delivery system to target hWAPL in cervical carcinoma. Mol. Cell Biochem., 2014, 391(1-2), 77-84.
60. Milgroom, A.; Intrator, M.; Madhavan, K.; Mazzaro, L.; Shandas, R.; Liu, B.; Park, D. Mesoporous silica nanoparticles as a breastcancer targeting ultrasound contrast agent. Colloids Surf. B Biointerfaces, 2014, 116, 652-657.
61. Liu, M.; Li, M.; Sun, S.; Li, B.; Du, D.; Sun, J.; Cao, F.; Li, H.; Jia, F.; Wang, T.; Chang, N.; Yu, H.; Wang, Q.; Peng, H. The use of antibody modified liposomes loaded with AMO-1 to deliver oligonucleotides to ischemic myocardium for arrhythmia therapy. Biomaterials, 2014, 35(11), 3697-3707.
62. Guo, P.; You, J.O.; Yang, J.; Jia, D.; Moses, M.A.; Auguste, D.T. Inhibiting Metastatic breast cancer cell migration via the synergy of targeted, pH-triggered siRNA delivery and chemokine axis blockade. Mol. Pharm., 2014
63. Cheng, J.; Teply, B.A.; Sherifi, I.; Sung, J.; Luther, G.; Gu, F.X.; Levy-Nissenbaum, E.; Radovic-Moreno, A.F.; Langer, R.; Farokhzad, O.C. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials, 2007, 28(5), 869-876.
64. Kim, D.; Jeong, Y.Y.; Jon, S. A drug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer. ACS Nano, 2010, 4(7), 3689-3696.
65. Youn, P.; Chen, Y.; Furgeson, D.Y. A myristoylated cellpenetrating peptide bearing a transferrin receptor-targeting sequence for neuro-targeted siRNA delivery. Mol. Pharm., 2014, 11(2), 486-495.
66. Winkler, J.; Martin-Killias, P.; Pluckthun, A.; Zangemeister- Wittke, U., EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins. Mol. Cancer Ther., 2009, 8(9), 2674-2683.
67. Yang, Z.Z.; Li, J.Q.; Wang, Z.Z.; Dong, D.W.; Qi, X.R. Tumortargeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas. Biomaterials, 2014, 35(19), 5226- 5239.
68. Majzoub, R.N.; Chan, C.L.; Ewert, K.K.; Silva, B.F.; Liang, K.S.; Jacovetty, E.L.; Carragher, B.; Potter, C.S.; Safinya, C.R. Uptake and transfection efficiency of PEGylated cationic liposome-DNA complexes with and without RGD-tagging. Biomaterials, 2014, 35(18), 4996-5005.
69. Cheng, C.J.; Saltzman, W.M. Enhanced siRNA delivery into cells by exploiting the synergy between targeting ligands and cellpenetrating peptides. Biomaterials, 2011, 32(26), 6194-6203.
70. Marrache, S.; Dhar, S. Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeutics. Proc. Natl. Acad. Sci. USA, 2012, 109(40), 16288-16293.
71. Hrkach, J.; Von Hoff, D.; Mukkaram Ali, M.; Andrianova, E.; Auer, J.; Campbell, T.; De Witt, D.; Figa, M.; Figueiredo, M.; Horhota, A.; Low, S.; McDonnell, K.; Peeke, E.; Retnarajan, B.; Sabnis, A.; Schnipper, E.; Song, J.J.; Song, Y.H.; Summa, J.; Tompsett, D.; Troiano, G.; Van Geen Hoven, T.; Wright, J.; Lo- Russo, P.; Kantoff, P.W.; Bander, N.H.; Sweeney, C.; Farokhzad, O.C.; Langer, R.; Zale, S. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci. Transl. Med., 2012, 4(128), 128ra39.
72. Zhou, F.; Zhang, J.; Li, P.; Niu, F.; Wu, X.; Wang, G.; Roberts, M.S. Toward a new age of cellular pharmacokinetics in drug discovery. Drug Metab. Rev., 2011, 43(3), 335-345.
73. Conner, S.D.; Schmid, S.L. Regulated portals of entry into the cell. Nature, 2003, 422(6927), 37-44.
74. Takei, K.; Haucke, V. Clathrin-mediated endocytosis: membrane factors pull the trigger. Trends Cell Biol., 2001, 11(9), 385-391.
75. Lu, J. J.; Langer, R.; Chen, J. A novel mechanism is involved in cationic lipid-mediated functional siRNA delivery. Mol. Pharm., 2009, 6(3), 763-771.
76. Rejman, J.; Bragonzi, A.; Conese, M. Role of clathrin- and caveolae- mediated endocytosis in gene transfer mediated by lipo- and polyplexes. Mol. Ther., 2005, 12(3), 468-474.
77. Zuhorn, I.S.; Kalicharan, R.; Hoekstra, D. Lipoplex-mediated transfection of mammalian cells occurs through the cholesteroldependent clathrin-mediated pathway of endocytosis. J. Biol. Chem., 2002, 277(20), 18021-18028.
78. Love, K.T.; Mahon, K.P.; Levins, C.G.; Whitehead, K.A.; Querbes, W.; Dorkin, J. R.; Qin, J.; Cantley, W.; Qin, L.L.; Racie, T.; Frank- Kamenetsky, M.; Yip, K.N.; Alvarez, R.; Sah, D.W.; de Fougerolles, A.; Fitzgerald, K.; Koteliansky, V.; Akinc, A.; Langer, R.; Anderson, D.G. Lipid-like materials for low-dose, in vivo gene silencing. Proc. Natl. Acad. Sci. USA, 2010, 107(5), 1864-1869.
79. Wang, Z.; Tiruppathi, C.; Minshall, R.D.; Malik, A.B. Size and dynamics of caveolae studied using nanoparticles in living endothelial cells. ACS Nano, 2009, 3(12), 4110-4116.
80. Cohen, A.W.; Hnasko, R.; Schubert, W.; Lisanti, M.P. Role of caveolae and caveolins in health and disease. Physiol. Rev., 2004, 84(4), 1341-1379.
81. Gabrielson, N.P.; Pack, D.W. Efficient polyethylenimine-mediated gene delivery proceeds via a caveolar pathway in HeLa cells. J. Control Release, 2009, 136(1), 54-61.
82. McIntosh, D.P.; Tan, X.Y.; Oh, P.; Schnitzer, J.E. Targeting endothelium and its dynamic caveolae for tissue-specific transcytosis in vivo: A pathway to overcome cell barriers to drug and gene delivery. Proc. Natl. Acad. Sci. USA 2002, 99(4), 1996-2001.
83. Schnitzer, J.E. Caveolae: From basic trafficking mechanisms to targeting transcytosis for tissue-specific drug and gene delivery in vivo. Adv. Drug Deliv. Rev., 2001, 49(3), 265-280.
84. Zhou, C.; Mao, Y.; Lee, L.J.; Lee, R.J. Quantitative analysis of intracellular and cytoplasmic siRNA delivery by SPANosomes. AAPS J., 2010, 12(S2), Abstract T2073.
85. Yu, B.; Wang, X.; Zhou, C.; Teng, L.; Ren, W.; Yang, Z.; Shih, C.H.; Wang, T.; Lee, R.J.; Tang, S.; Lee, L.J. Insight into mechanisms of cellular uptake of lipid nanoparticles and intracellular release of small RNAs. Pharm. Res., 2014.
86. Zhou, C.; Zhang, Y.; Lee, L.J.; Lee, R.J. Synthesis and characterization of a lipoidal amine-based nanocarrier (LANC) formulation for small interfering RNA (siRNA) delivery. AAPS J., 2011, 13(S2), Abstract T3030.
87. Wang, X.; Yu, B.; Ren, W.; Mo, X.; Zhou, C.; He, H.; Jia, H.; Wang, L.; Jacob, S. T.; Lee, R.J.; Ghoshal, K.; Lee, L.J. Enhanced hepatic delivery of siRNA and microRNA using oleic acid based lipid nanoparticle formulations. J. Control Release, 2013, 172(3), 690-8.
88. Dollery, C.T. Intracellular drug concentrations. Clin. Pharmacol. Ther., 2013, 93(3), 263-266.
89. Zhou, C.; Shen, P.; Cheng, Y. Quantitative study of the drug efflux kinetics from sensitive and MDR human breast cancer cells. Biochim. Biophys. Acta, 2007, 1770(7), 1011-1020.
90. Bartlett, D.W.; Davis, M.E. Insights into the kinetics of siRNAmediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res., 2006, 34(1), 322-333.
91. O'Brien, S.M.; Cunningham, C.C.; Golenkov, A.K.; Turkina, A.G.; Novick, S.C.; Rai, K.R. Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. J. Clin. Oncol., 2005, 23(30), 7697-7702.
92. Jahrsdorfer, B.; Jox, R.; Muhlenhoff, L.; Tschoep, K.; Krug, A.; Rothenfusser, S.; Meinhardt, G.; Emmerich, B.; Endres, S.; Hartmann, G., Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN. J. Leukoc. Biol., 2002, 72(1), 83-92.
93. Rubin, E.H.; Agrawal, N.G.; Friedman, E.J.; Scott, P.; Mazina, K.E.; Sun, L.; Du, L.; Ricker, J.L.; Frankel, S.R.; Gottesdiener, K.M.; Wagner, J.A.; Iwamoto, M. A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer. Clin. Cancer Res., 2006, 12(23), 7039-7045.
94. Gekeler, V.; Gimmnich, P.; Hofmann, H.P.; Grebe, C.; Rommele, M.; Leja, A.; Baudler, M.; Benimetskaya, L.; Gonser, B.; Pieles, U.; Maier, T.; Wagner, T.; Sanders, K.; Beck, J.F.; Hanauer, G.; Stein, C.A. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice. Oligonucleotides, 2006, 16(1), 83-93.
95. Yu, B.; Mao, Y.; Bai, L.Y.; Herman, S.E.; Wang, X.; Ramanunni, A.; Jin, Y.; Mo, X.; Cheney, C.; Chan, K.K.; Jarjoura, D.; Marcucci, G.; Lee, R.J.; Byrd, J.C.; Lee, L.J.; Muthusamy, N. Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia. Blood, 2013, 121(1), 136-147.
96. Yang, X.; Peng, Y.; Yu, B.; Yu, J.; Zhou, C.; Mao, Y.; Lee, L.J.; Lee, R.J. A covalently stabilized lipid-polycation-DNA (sLPD) vector for antisense oligonucleotide delivery. Mol. Pharm., 2011, 8(3), 709-715.
97. Yang, Z.; Yu, B.; Zhu, J.; Huang, X.; Xie, J.; Xu, S.; Yang, X.; Wang, X.; Yung, B.C.; Lee, L.J.; Lee, R.J.; Teng, L. A microfluidic method to synthesize transferrin-lipid nanoparticles loaded with siRNA LOR-1284 for therapy of acute myeloid leukemia. Nanoscale, 2014, 6(16), 9742-9751.
98. Dams, E.T.; Laverman, P.; Oyen, W.J.; Storm, G.; Scherphof, G.L.; van Der Meer, J.W.; Corstens, F.H.; Boerman, O.C. Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J. Pharmacol. Exp. Ther., 2000, 292(3), 1071-1079.
99. Ishida, T.; Ichihara, M.; Wang, X.; Yamamoto, K.; Kimura, J.; Majima, E.; Kiwada, H. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J. Control Release, 2006, 112(1), 15-25.
100. Lv, H.; Zhang, S.; Wang, B.; Cui, S.; Yan, J. Toxicity of cationic lipids and cationic polymers in gene delivery. J. Control Release, 2006, 114(1), 100-109.
101. Volkovova, K.; Ulicna, O.; Kucharska, J.; Handy, R.; Staruchova, M.; Kebis, A.; Pribojova, J.; Tulinska, J.; Dusinska, M. Health effects of selected nanoparticlesin vivo: Liver function and hepatotoxicity following intravenous injection of titanium dioxide and Na-oleate coated iron oxide nanoparticles in rodents. Nanotoxicology, 2013.
102. Dokka, S.; Toledo, D.; Shi, X.; Castranova, V.; Rojanasakul, Y. Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes. Pharm. Res., 2000, 17(5), 521-525.
103. Tabernero, J.; Shapiro, G.I.; LoRusso, P.M.; Cervantes, A.; Schwartz, G.K.; Weiss, G.J.; Paz-Ares, L.; Cho, D.C.; Infante, J.R.; Alsina, M.; Gounder, M.M.; Falzone, R.; Harrop, J.; White, A.C.; Toudjarska, I.; Bumcrot, D.; Meyers, R.E.; Hinkle, G.; Svrzikapa, N.; Hutabarat, R.M.; Clausen, V.A.; Cehelsky, J.; Nochur, S.V.; Gamba-Vitalo, C.; Vaishnaw, A.K.; Sah, D.W.; Gollob, J.A.; Burris, H.A. 3rd, First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov., 2013, 3(4), 406-417.
104. Kanasty, R.; Dorkin, J. R.; Vegas, A.; Anderson, D., Delivery materials for siRNA therapeutics. Nat. Mater., 2013, 12(11), 967- 977.
105. Weinstein, I.B.; Joe, A.K. Mechanisms of disease: Oncogene addiction-- a rationale for molecular targeting in cancer therapy. Nat. Clin. Pract. Oncol., 2006, 3(8), 448-457.
106. Liu, Y.; Ji, M.; Wong, M.; Joo, K.; Wang P. Enhanced therapeutic efficacy of iRGD-conjugated crosslinked multilayer liposomes for drug delivery. BioMed Res. Int., 2013, 378380.